Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet

被引：0
|
作者：
Pantaleo, Maria A. [1 ,2 ]
Nannini, Margherita [1 ]
机构：
[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Specialized Expt & Diagnost Med, Via Massarenti 9, I-40138 Bologna, Italy
[2] Univ Bologna, Giorgio Prodi Canc Res Ctr, Via Massarenti 11, I-40138 Bologna, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 58卷
关键词：
SUCCINATE-DEHYDROGENASE; FUNCTION MUTATIONS; WT GIST; PDGFRA; SDHA; KIT;
D O I：
10.1016/j.ejca.2016.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：38 / 40
页数：3
相关论文
共 16 条
  • [1] Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
    Patrikidou, Anna
    Domont, Julien
    Chabaud, Sylvie
    Ray-Coquard, Isabelle
    Coindre, Jean-Michel
    Bui-Nguyen, Binh
    Adenis, Antoine
    Rios, Maria
    Bertucci, Francois
    Duffaud, Florence
    Chevreau, Christine
    Cupissol, Didier
    Perol, David
    Emile, Jean-Francois
    Blay, Jean-Yves
    Le Cesne, Axel
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 173 - 180
  • [2] Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
    Blay, Jean-Yves
    Devin, Quentin
    Duffaud, Florence
    Toulmonde, Maud
    Firmin, Nelly
    Collard, Olivier
    Bompas, Emmanuelle
    Verret, Benjamin
    Ray-Coquard, Isabelle
    Salas, Sebastien
    Henon, Clemence
    Honore, Charles
    Brahmi, Mehdi
    Dufresne, Armelle
    Pracht, Marc
    Hervieu, Alice
    Penel, Nicolas
    Bertucci, Francois
    Rios, Maria
    Saada-Bouzid, Esma
    Soibinet, Pauline
    Perol, David
    Chabaud, Sylvie
    Italiano, Antoine
    Le Cesne, Axel
    LANCET ONCOLOGY, 2024, 25 (09): : 1163 - 1175
  • [3] Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours
    Pantaleo, Maria Abbondanza
    Nannini, Margherita
    Saponara, Maristella
    Gnocchi, Chiara
    Di Scioscio, Valerio
    Lolli, Cristian
    Catena, Fausto
    Astolfi, Annalisa
    Di Battista, Monica
    Biasco, Guido
    ANTI-CANCER DRUGS, 2012, 23 (05) : 567 - 572
  • [4] The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
    Goerres, GW
    Stupp, R
    Barghouth, G
    Hany, TF
    Pestalozzi, B
    Dizendorf, E
    Schnyder, P
    Luthi, F
    von Schulthess, GK
    Leyvraz, S
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (02) : 153 - 162
  • [5] The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
    G. W. Goerres
    R. Stupp
    G. Barghouth
    T. F. Hany
    B. Pestalozzi
    E. Dizendorf
    P. Schnyder
    F. Luthi
    G. K. von Schulthess
    S. Leyvraz
    European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 : 153 - 162
  • [6] Impact of mutational status and other prognostic factors on survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group
    Domont, Julien
    Chabaud, Sylvie
    Coquard, Isabelle Ray
    Bui, Binh
    Adenis, Antoine
    Rios, Maria
    Bertucci, Francois
    Duffaud, Florence
    Cupissol, Didier
    Chevreau, Christine
    Bompas, Emmanuelle
    Emile, Jean-Francois
    Coindre, Jean-Michel
    Blay, Jean-Yves
    Le Cesne, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group
    Bertucci, F.
    Blay, J.
    Ray-Coquard, I. L.
    Nguyen, B. Bui
    Adenis, A.
    Rios, M.
    Duffaud, F.
    Cupissol, D.
    Chevreau, C.
    Bompas, E.
    Cioffi, A.
    Nehal, L.
    Perol, D.
    Le Cesne, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Long-term Survival on S0033-a Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours (GISTs)
    Blanke, C.
    Rankin, C.
    Benjamin, R. S.
    Raymond, A. K.
    Heinrich, M. C.
    Fletcher, C. D. M.
    Crowley, J.
    Borden, E. C.
    Demetri, G. D.
    Baker, L. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S664 - S664
  • [9] Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.
    Blanke, C. D.
    Demetri, G. D.
    Von Mehren, M.
    Heinrich, M. C.
    Eisenberg, B. L.
    Fletcher, J.
    Corless, C. L.
    Wehrle, E.
    Sandau, K. B.
    Joensuu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 526S - 526S
  • [10] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Blanke, Charles D.
    Demetri, George D.
    von Mehren, Margaret
    Heinrich, Michael C.
    Eisenberg, Burton
    Fletcher, Jonathan A.
    Corless, Christopher L.
    Fletcher, Christopher D. M.
    Roberts, Peter J.
    Heinz, Daniela
    Wehre, Elisabeth
    Nikolova, Zariana
    Joensuu, Heikki
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 620 - 625
12